NasdaqGS:IMVTBiotechs
Can IMVT-1402’s Phase 2 RA Data Reframe Immunovant’s (IMVT) Autoimmune Pipeline Narrative?
Recent commentary on Immunovant’s IMVT-1402 program highlighted high response rates in a completed Phase 2 rheumatoid arthritis trial, including in patients who had already received multiple advanced therapies.
This focus on difficult-to-treat patients has pushed IMVT-1402 to the center of Immunovant’s story, raising questions about how such response rates could shape expectations for its broader autoimmune pipeline.
We’ll now look at how the strong IMVT-1402 Phase 2 responses in difficult...